ArticleResearch in pharmaceutical sciences2025
Effect of resveratrol on key signaling pathways including SIRT1/AMPK/Smad3/TGF-β and miRNA-141 related to NAFLD in an animal model.
Article in Research in pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Effects of PPARα, PPARγ, and dual PPARα/γ agonists on liver tissue and biochemical markers in NAFLD-induced Wistar rats.Research in pharmaceutical sciences · 2026Article
- STAT Signaling in Metabolic Disorders: From Molecular Mechanisms to Therapeutic Implications.Cell biochemistry and biophysics · 2026Review
- Resveratrol for Cancer Treatment: Effects on Metabolism and Immune Cells.Biomolecules · 2026Review
- TGF-beta inhibitors in cancer therapy: a review of the TGF-beta signal transduction pathway and current developments.EXCLI journal · 2026Review
- A Small Molecule Compound, Berberine Reduces IgE but Not IgG Production via Promoting miRNA-34a-p53 Axis.Cells · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Non-alcoholic fatty liver disease (NAFLD) is a chronic metabolic condition characterized by the accumulation of excess fat in the liver, which can ultimately lead to fibrosis and cirrhosis. This study investigated the impact of resveratrol on the signaling pathways miR-141/SIRT1/AMPK/TGF- p/Smad3 in fatty liver of male C57/BL6 mice. Experimental approach: Twenty-one male C57/BL6 mice were acclimatized for 10 days and divided into 3 groups (n = 7), including control, NAFLD, and NAFLD + resveratrol groups. After an 8-week HFD to induce NAFLD, the mice were treated with resveratrol (100 mg/kg/day; oral gavage) for 8 weeks. At the end of the study (16 weeks), serum and liver tissue samples were collected. Gene expression was assessed using RT- PCR, while protein levels were analyzed Findings/Results: The results of the study showed that the expression levels of the genes Smad3 and miRNA- 141 were significantly reduced in the resveratrol-treated group compared to the NAFLD group, while the expression levels of SIRT1 and TGF-β were significantly increased. In addition, the Western blot results indicated that the levels of the proteins P-AMPK and SIRT1 in the resveratrol-treated group were significantly higher compared to the NAFLD group. Furthermore, a significant reduction in fat accumulation and degeneration was observed in the histopathological findings of the liver in the resveratrol-treated group. Conclusion and implications: The study concluded that resveratrol has the potential to reduce liver damage from NAFLD by modulating various signaling pathways, particularly TGF-β/Smad3, SIRT1/AMPK, and miRNA-141, leading to improved lipid metabolism and reduced hepatic steatosis. While the findings underscored the multifaceted therapeutic effects of resveratrol, further research and clinical trials are necessary to fully understand its mechanisms and applications in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.